| | Webinar: 2021 Apollo Healthcare Predictions Thursday, February 4, 2021 | 1pm ET / 10am PT With so much disruption from COVID-19, this year’s global insights will provide a unique window into the minds of those professionals perhaps most tested by 2020 and their hopes and perspectives for 2021. Register Now! |
Novartis says it's ready to pitch in on manufacturing rivals' COVID-19 vaccines, diagnostics Docs call on Biden to include medical groups in COVID-19 vaccine distribution Pfizer and Moderna haven't proven their COVID-19 vaccines shield against new variants: analysts Scramble for specialty syringes as Pfizer, feds look to extract 6th vaccine doses Businessman charged with hoarding PPE, price gouging health providers DOD taps Pharm-Olam for repurposed Humira COVID-19 test Mammoth Biosciences teams with Agilent to deliver CRISPR-based coronavirus tests COVID-19 tracker: Germany recommends against AZ shot in 65+ age group; South African variant found in U.S. Johns Hopkins, Mount Sinai turning to virtual rehab and video games to help patients recover from strokes Medigene shares sag as it axes TCR-T blood cancer drug, with COVID-19 partly to blame Featured Story | By Eric Sagonowsky Right after Sanofi stepped in to help produce Pfizer/BioNTech coronavirus vaccines in Europe, Novartis is exploring whether it can deploy its own manufacturing network to boost COVID-19 supplies. Separately, the U.S. is weighing the Defense Production Act to compel drugmakers to produce Pfizer or Moderna mRNA vaccines. read more |
| |
|---|
|
Top Stories By Tina Reed Medical practices are largely being left out of the COVID-19 vaccine efforts, the Medical Group Management Association found. read more By Arlene Weintraub Moderna and Pfizer have been quick to unveil data suggesting their COVID-19 mRNA vaccines have some efficacy against coronavirus mutants emerging in the U.K., South Africa and Brazil. But some pharma watchers have scoured the data, and they're not so convinced. read more By Beth Snyder Bulik,Fraiser Kansteiner Syringe makers are scrambling to meet demand for so-called low dead space syringes as Pfizer and the U.S. look to squeeze out extra vaccine doses. Physicians and pharmacists discovered the potential extra dose after they began vaccinating patients, but initial enthusiasm has been dampened by the requirement of the now-scarce specialty needles to extract the last bit from each vial. read more By Tina Reed A Mississippi man was charged with allegedly attempting a $1.8 million scheme to hoard personal protective equipment and price gouging healthcare providers, including several U.S. Department of Veterans Affairs hospitals. read more By Ben Adams Pharm-Olam has been handed a Department of Defense contract to run a mid- to late-stage trial of blockbuster autoimmune and inflammation drug adalimumab. read more By Conor Hale CRISPR-wielder Mammoth Biosciences will team up with Agilent Technologies to help launch its upcoming COVID-19 diagnostic test, designed to handle more than 4,000 samples per day. read more By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale German officials have recommended against using AstraZeneca's COVID-19 vaccine in people 65 and older, citing a lack of evidence in the age group. Meanwhile, Europe is facing pressure to restrict vaccine exports after the news that AZ won't be able to fulfill its first-quarter order for the bloc. read more By Brian T. Horowitz The COVID-19 pandemic has brought experimentation in all different types of remote care, and that includes neuroscience. Health systems including Mount Sinai and Johns Hopkins are working with digital therapeutics company MindMaze to use video-based therapy and gamification to help stroke victims recover at home. read more By Ben Adams German biotech Medigene saw its shares down 7% Thursday after it decided to cull one of its TCR-T cancer assets after delays by COVID-19 restrictions hampered its efforts. read more |
